Diversity-promoting Institutions Drug Abuse Research Development Program (DIDARP)
10th Drug Abuse Research Symposium Schedule
Keynote Speaker: Joanna Fowler, Ph.D.*
Tenured Chemist, Biosciences, U.S. Department of Energy’s Brookhaven National Laboratory
*This specific lecture is a 1.0 AMA PRA Category 1 CreditTM certified CME event, affiliated with Drug Abuse Research Day*
(this lecture is the only CME offered within the agenda)
Upon completion Joanna Fowler, Ph.D. session, participants will be able to:
1. Describe PET technology
2. Recognize the brain dopamine system and the response of the dopamine system to drugs of
abuse vs natural reinforces like food
3. Identify the pharmacokinetics of cocaine in the human brain and the relationship to the ‘high’.
4. Describe dopamine D2 receptor availability in the human brain in addicted individuals.
5. Identify orbital frontal cortex metabolism in addicted individuals
6. Describe non-nicotine effects of tobacco smoke exposure on the human brain.
7. Summarize the effects of addiction on public health
Physician Continuing Medical Education
Accreditation Statement: Charles R. Drew University is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physician Credit Designation:
Charles R. Drew University designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For information about the accreditation of this program, please contact Charles R. Drew University at 323.563.9349 or firstname.lastname@example.org.
Instructions to Receive Credit: In order to receive credit for this activity, the participant must submit a completed Evaluation/Request for Credit Form to the CME Office. A Statement of Credit will be issued only upon receipt of a Completed Activity Evaluation/Request for Credit Form. Statements of Credit will be emailed to you on a quarterly basis.
Non-physicians who successfully complete the activity will receive a Certificate of Participation. A Certificate of Participation will be issued only upon receipt of a completed Activity Evaluation/Request for Credit Form. Certificates of Participation will be emailed to you on a quarterly basis.
Fee Information: There is no fee for this educational activity.
Disclosure of Conflicts of Interest: Charles R. Drew University requires instructors, planners, managers and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Charles R. Drew University for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Americans with Disabilities Act:
éEvent staff will be gladly assist you with any special needs. Please contact Jeonathan Rodriguez prior to the live event at 323.563.9349 or email@example.com.
The Diversity-Promoting Institution Drug Abuse Research Program (DIDARP) (R24DA017298) has been funded by the National institute of Drug Abuse (NIDA) since 2004 and was funded for 5 years in 2014. Theodore C. Friedman, MD, PhD is the program director and Vishnudutt Purohit, Ph.D is the NIDA program officer. The theme of DIDARP 2014-2019 is “Metabolic Effects of Nicotine: It Matters.” Our training theme is “Research Teams of the Future”
The overarching goal of the research, training and education programs of this DIDARP is to enhance CDU’s capacity to conduct substance abuse research with a primary focus on the metabolic effects of nicotine. The specific goals of CDU DIDARP are:
- To increase the number of high quality drug addiction research projects related to the metabolic effects of nicotine to allow CDU to develop expertise and acquire preliminary data to be able to compete for NIDA P01, P50 or R01 grants;
- To continue to foster interest in substance abuse research among under-represented students and other trainees by providing meaningful educational and research experiences; and
- To continue to enhance the research infrastructure at CDU to support substance abuse research.
There are currently three research projects on DIDARP:
- Project 1: Nicotine exacerbates high fat diet-induced hepatic steatosis and skeletal muscle abnormalities in obese mice. PI: Amiya Sinha-Hikim, PhD
- Pilot Project A: Understanding the role of dopamine in binge-eating, nicotine and alcohol use: a translational PET study. PI: Amira Brown, PhD
- Pilot Project B: The association between secondhand smoking and diabetes, obesity and other chronic diseases. PI, Dulcie Kermah, MPH
- Achieving these goals will eventually help reduce the health disparities as related to substance abuse.
MIDARP hosts a yearly symposium showcasing research on substance abuse from CDU and its affiliates.
The 9th Drug Abuse Research Symposium occurred on Friday, September 12, 2014. Talks (.mp4), slides, pictures and Biosketches of speakers and abstracts of student presentations are available.
The 8th Drug Abuse Research Symposium occurred on Friday, June 14, 2013. Talks (.mp4), slides, pictures and Biosketches of speakers and abstracts of student presentations are available.
The 7th drug abuse research conference occurred on August 17, 2012. Talks (.mp4), slides, pictures and Biosketches of speakers and abstracts of student presentations are available.
The 6th drug abuse research conference. occurred on August 10, 2010 and talks and schedule can be viewed.The schedule of prior drug abuse research conferences can also be viewed.
The 5th drug abuse research conference occurred on July 31, 2009.
The 4th drug abuse research conference ) occurred on September 26, 2008.
The 3rd drug abuse research conference occurred on February 7, 2007.
The 2nd drug abuse research conference occurred on August 6, 2006.
The 1st drug abuse research conference occurred on July 28, 2005.
Selected slides or abstracts may be available from Dr. Friedman (mailto:mailto:firstname.lastname@example.org ).
For more information about drug abuse research at CDU, please contact Dr. Friedman at 310-668-5197 or mailto:mailto:email@example.com